Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Can-Fite BioPharma Ltd is a biotechnology business based in the US. Can-Fite BioPharma shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $1.31 |
|---|---|
| 52-week range | $0.94 - $3.07 |
| 50-day moving average | $1.30 |
| 200-day moving average | $1.84 |
| Wall St. target price | $6.08 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.31 from 2022-01-14
| 1 week (2022-01-07) | 2.34% |
|---|---|
| 1 month (2021-12-17) | 3.15% |
| 3 months (2021-10-15) | -15.48% |
| 6 months (2021-07-16) | -43.29% |
| 1 year (2021-01-15) | -31.05% |
|---|---|
| 2 years (2020-01-16) | -52.36% |
| 3 years (2019-01-16) | 1.55% |
| 5 years (2017-01-13) | 2.36 |
| Revenue TTM | $799,000 |
|---|---|
| Gross profit TTM | $763,000 |
| Return on assets TTM | -55.28% |
| Return on equity TTM | -128.53% |
| Profit margin | 0% |
| Book value | $0.48 |
| Market capitalisation | $27.4 million |
TTM: trailing 12 months
We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.
Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.
Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $0.9402 up to $3.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.6889. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.